Sight Sciences, Inc.
SGHTHealthcareNASDAQMedical Devices · Last scanned Jun 23, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Sight Sciences, Inc. focuses on Medical Devices services and products. Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in. The company carries a $285.1M market cap, placing it firmly in the micro-cap category. The company operates in two segments, Surgical Glaucoma and Dry Eye.
Market Cap
$285.1M
Beta
2.40
P/E (TTM)
—
P/E (Fwd)
-7.94
EPS (TTM)
$-0.70
EPS (Fwd)
$-0.66
ROE
-56.6%
ROA
-14.3%
Cash
$85.0M
Total Debt
$41.8M
Free CF
-$8.6M
52W Change
23.0%
Annual Financials
Cash vs Debt
With $85.0M in cash and $41.8M in debt, SGHT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$8.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -56.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $71.3M (2022) to $77.4M (2025).
A beta of 2.40 means SGHT is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SGHT.